Keywords
How to Cite
Abstract
There are numerous data in experimental and clinical medicine that convincing evidence on the leading role of the immune system in the pathogenesis of tumor diseases. Exactly immune cells such as cytotoxic T lymphocytes, NK cells, macrophages and dendritic cells have the ability to kill tumor cells. Under normal conditions the activity of these cells is a factor of inhibition proliferation and differentiation of tumor cells. An appearance of tumor itself, as uncontrolled cell growth and clinical manifestation, says that it was changed the cytotoxic activity of the cells causing tumor immunity. The main factor, if not the only reason for the decline of anti-tumor activity of the cells, is the formation of powerful extra- and inside-tumor suppressor mechanisms suppressing cytotoxic activity of anti-tumor immune-competent cells and allowing tumor cells to avoid surveillance by the immune system. It is showed that T and B cells, macrophages, and cells of myeloid origin suppressors possess these immunosuppressive properties. Therefore, in the future, methods to suppress functional activity of cells suppressors of various geneses can be the basis for immunotherapy of tumor growth.References
Betts G., Jones E., Junaid S. et al. Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer // Gut. - 2012. - Vol. 61. - P 1163-1171.
Byrne W.L., Mills K.H., Lederer J.A. et al. Targeting regulatory T cells in cancer // Cancer Res. - 2011. - Vol. 71. - P. 6915-6920.
Cao X. Regulatory T cells and immune tolerance to tumors // Immunol. Rev. - 2010. - Vol. 46. - P 79-93.
Chang L.Y., Lin Y.C., Mahalingham J. et al. Tumor-derived chemokine CCL5 enhances TGF- -mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells // Cancer Res. - 2012. - Vol. 72. - P 1092-1102.
Chavez-Galan L., Olleros M.L., Vesin D., Garcia I. Much more than M1 and M2 macrophages, there are also CD169+ and TCR+ macrophages // Frontiers in Immunology. - 2015. - Vol. 6. - P. 1-15.
Chen M.L., Pittet M.J., Gorelik L. et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo // Proc Natl Acad Sci USA. -2005. - Vol. 102. - P. 419-424.
Chen W., Jin W., Hardegen N. et al. Conversion of peripheral CD4+CD25- naïve T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 // J. Exp. Med. - 2003. - Vol. 198. - P. 1875-1886.
Conejo-Garcia J.R., Benencia F., Courregges M.C. et al. Tumor-infiltrating dendritic cell precursors recruited by a ß-defensing contribute to vasculogenesis under the influence of Vegf-A // Nature Medicine. - 2004. - Vol. 10. - № 9. - P. 950-958.
Delgoffe G.M., Woo S.R., Tumis M.E. et al. Stability and function of regulatory T cells is maintained by a neuropi-lin-1-semaphorin-4a axis // Nature. - 2013. - Vol. 501. - P. 252-256.
Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting // Nat Rev Immunol. - 2006. - Vol. 6 (11). - P. 836-848.
Gabrilovich D.I., Corak J., Ciernik I.F. et al. Decreased antigen presentation by dendritic cells in patients with breast cancer // Clin. Cancer Res. - 1997. - Vol. 3. - P 483-490.
Gabrilovich D.I., Nagarai S. Myeloid-derived suppressor cells as regulator of the immune system // Nature Rev. Immunol. - 2009. - Vol. 162. - № 9. - P 162-174.
Gallina G., Dolcetti L., Serafini P. et al. Tumors induce a subset of inflammatory monocytes with immuno suppressive activity on CD8+ T cells // J. Clin. Invest. - 2006. - Vol. 116 - № 10. - P. 2777-2790.
Ghiringhelli F., Puig P.E., Roux S. et al. Tumor cells covert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation // J. Exp. Med. - 2005. - Vol. 202. - P 919-929.
Gondek D.C., Lu L.F., Quezada S.A. et al. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism // J. Immunol. - 2005. - Vol. 174. - P 1783-1786.
Grossman W.J., Verbsky J.W., Barchet W. et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death // Immunity. - 2004. - Vol. 21. - P. 589-601.
Hahn B.H., Singh R.P., La Cava A., Ebling F.M. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistent, TGFbeta-secreting CD8+ T cell suppressors // J. Immunol. - 2005. Vol. 175. - P 7728-7737.
Huang B1, Pan P.Y., Li Q., Sato A.I., Levy DE, Bromberg J, Divino CM, Chen SH. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host // Cancer Res. - 2006. - Vol. 66. - № 2. - P. 1123-1131.
Janikashvili N., Bonnotte B., Katsanis E., Larmonier N. The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance // Clinical and Developmental Immunology. - Vol. 2011 (2011), Article ID 430394, 14 pages.
Killinc M.O., Rowswell-Turner R.B., Gu T. et al. Activated CD8+ T-effector/memory cells eliminate CD4+CD25+Foxp3+ T-suppressor cells from tumor via FasL mediated apoptosis // J. Immunol. - 2009. - Vol. 183. - P 7656-7660.
Laoui D., Movahedi K., van Overmeire E. et al. Tumor-associated macrophages in breast cancer: distinct subsets, distinct function // Int. J. Dev. Biol. - 2011. - Vol. 55. - P. 861-867.
Li H., Han Y., Guo Q., Zhang M. et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1 // J. Immunol. - 2009. - Vol. 182. - № 1. - P 240-249.
Lin E.Y., Li J.-F., Gnatovskiy L. et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer // Cancer Res. - 2006. - Vol. 66. - P 11238-11246.
Loser K., Apelt J., Voskort M., Mohaupt M. et al. IL-10 controls ultraviolet-induced carcinogenesis in mice // J. Immunol. - 2007. - Vol. 179. - P 365-371.
Maj T., Zou W. Dendritic cells are stressed out in tumor // Cell Research. - 2015. doi:10.1038/cr.2015.93
Mandapathil M., Hilldorfer B., Szczepanski M.J. et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells // J. Biol. Chem. - 2010. - Vol. 285. - P. 7176-7186.
Monu N.R., Frey A.B. Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship // Immunol. Invest. - 2012. - Vol. 41. - № 6-7. - P 595-613.
Moseman E.A., Liang X., Dawson A.J. et al. Human plasmacytoid dendritic cells activated oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells // J. Immunol. - 2004. -Vol. 173. - P 4433-4442.
Munn D.H., Sharma M.D., Baban B. et al. GCN2 kinase in T cells mediated proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase // Immunity. - 2005. - Vol. 22. - P. 633-642.
Nefedova Y., Huang M., Kusmartsev S. et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer // J. Immunol. - 2004. - Vol. 172. - № 1. - p 464-474.
Pandiyan P., Zheng L., Ishihara S. et al. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells // Nat. Immunol. -2007. - Vol. 8. - P. 1353-1353.
Pasare C., Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ Tcell-mediated suppression by dendritic cells // Science. - 2003. - Vol. 299. - P. 1033-1036.
Peng G., Wang H.Y., Peng W. et al. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanism controlled by a unique toll-like receptor signaling pathway // Immunity. - 2007. - Vol. 27. - P. 334-348.
Russell J.H., Ley T.J. Lymphocyte-mediated cytotoxicity // Annu Rev Immunol. - 2002. - Vol. 20. - P. 323-70
Sakaguchi S., Miyara M., Costantino C.M., Hafler, D.A. FOXP3+ regulatory T cells in the human immune system // Nat. Rev. Immunol. - 2010. - Vol. 10. - P. 490-500.
Shah S., Divekar A.A., Hilchey S.P. et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and Th1 cytokine responses by B cells // Int. J. Cancer. - 2005. - Vol. 117. - P. 574-586.
Shankaran V., Ikeda H., Bruce A.T. et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity // Nature. - 2001. - Vol. 26. - 410 (6832). - P. 1107-1111
Sharma M.D., Baban B., Chandler P. et al. Plasmacytoid dendritic cells from tumor-draining lymph nodes activate mature Treg via indoleamine 2,3-dioxygenase // J. Clin. Invest. - 2007. - Vol. 117. - P. 2570-2582.
Smyth M.J., Trapani J.A. Lymphocyte-mediated immunosurveillance of epithelial cancers? // Trends Immunol. - 2001. - Vol. 22 (8). - P. 409-11.
Solito S., Pinton L., Damuzzo V., Mandruzzato S. Highlights on molecular mechanisms of MDSC-mediated immune suppression: paving the way for new working hypotheses // Immunol. Invest. - 2012. - Vol. 41. - № 6-7. - P. 722-733.
Strauss L., Bergmann C., Whiteside T.L. Human circulating CD4+CD25+ high Foxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis // J. Immunol. - 2009. - Vol. 182. - P. 1469-1480.
Tokuno K., Hazama S., Yoshimo S. et al. Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer // Anticancer Res. - 2009. - Vol. 29. - P. 1527-1532.
Vieira P.L., Christensen J.R., Minaee S. et al. IL-10-secreting regulatory T cells do not express Foxp3 but have function to naturally occurring CD4+CD25+ regulatory T cells // J. Immunol. - 2004. - Vol. 172. - P. 5986-5893.
Whiteside T.L. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? // Cancer Immunol. Immunother. - 2014. - Vol. 63 (1). - P. 67-72.
Wing K., Onishi Y., Prieto-Martin P. et al. CTLA-4 control over Foxp3+ regulatory T cell function // Science. - 2008. - Vol. 322. - P. 271-275.
Xiang X., Poliakov A., Liu C. et al. Induction of myeloid-derived suppressor cells by tumor exosomes // Int. J. Cancer. - 2009. - Vol. 124. - № 11. - P. 2621-2633.
Zhou G., Drake C.G., Levitsky H.L. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines // Blood. - 2006. - Vol. 107. - P. 628-636.
Zou W. Regulatory T cells, tumour immunity and immunotherapy // Nat Rev Immunol. - 2006. - Vol. 6. - P. 295-307.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...